News

ViCentra has launched its next‑generation smartphone‑controlled Kaleido automated insulin delivery patch pump system, marking a major step toward more seamless hybrid closed‑loop therapy for people with diabetes in Germany and the Netherlands. The new version combines the Kaleido patch pump with Diabeloop’s DBLG2 self‑learning algorithm and Dexcom G7 continuous glucose monitoring (CGM), enabling users to control the system directly from their smartphone rather than a separate dedicated handset.

As per Astute Analytica, insulin pump market was valued at US$ 6.10 billion in 2024 and is projected to hit the market valuation of US$ 25.40 billion by 2033 at a CAGR of 17.2% during the forecast period 2025–2033.

Global Diabetes Burden and Insulin‑Requiring Population

Approximately 590 million adults aged 20–79 live with diabetes worldwide, or about 1 in 9 adults, according to the International Diabetes Federation’s 2024 Atlas. WHO‑linked estimates for all ages put the figure even higher, at around 830 million people with diabetes globally in 2022.

A substantial subset of these patients requires external insulin. Published modeling and expert reviews suggest that roughly 150–200 million people worldwide currently need insulin therapy—encompassing nearly all individuals with type 1 diabetes plus many with advanced type 2 diabetes. Within this group, access remains a critical challenge: WHO and charity reports indicate that only about half of people who need insulin actually receive it, with the shortfall worst in low‑ and middle‑income countries

What the New System Offers?

The upgraded Kaleido‑DBLG2‑Dexcom G7 configuration is designed to fit more naturally into daily life, with a compact, lightweight patch pump and a smaller, all‑in‑one CGM sensor and transmitter. By integrating these components, ViCentra aims to simplify insulin automation, reduce device clutter, and give users more flexibility in how and where they wear their pump. The system continues Kaleido’s focus on design and personalization, offering customizable aluminum shells in multiple colors so users can tailor the device to their lifestyle.

Users will be able to start therapy today on Kaleido with Diabeloop’s DBLG1 algorithm and then transition smoothly to the new DBLG2‑based system later in the summer, once the commercial rollout begins. This staged approach allows healthcare professionals to initiate automated insulin delivery now while keeping the route clear to the more advanced closed‑loop configuration when it becomes available.

Launch Rollout and Commercial Plans

ViCentra plans first commercial deliveries of the new smartphone‑controlled system in Germany and the Netherlands later this summer, following an initial pilot in the Netherlands. The company will formally introduce the new platform at the 60th DDG Diabetes Congress in Berlin from 13–15 May 2026, where it will be exhibiting and hosting meetings with clinicians, partners, and other stakeholders.

Over the past year, ViCentra has expanded its commercial presence in these markets, strengthened operational readiness, and built the infrastructure needed to support future growth across Europe and, eventually, the United States. The launch of Kaleido with DBLG2 and Dexcom G7 is positioned as a key milestone in the company’s broader strategy to scale a differentiated insulin‑delivery platform and broaden access to automated insulin therapy for people with type 1 diabetes.